Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
The Cooper Companies, Inc. is a global medical device company operating primarily in the eye care and women’s health industries. The company focuses on products that improve vision, fertility, and reproductive health outcomes, serving both healthcare professionals and patients worldwide. Its business model is centered on specialized, clinically driven markets with recurring demand and high regulatory barriers.
The company operates through two primary business lines: CooperVision, which generates the majority of revenue through contact lenses, and CooperSurgical, which provides medical devices and services for women’s health and fertility. Founded in 1958 and later restructured into its current form in the 1980s and 1990s, The Cooper Companies has evolved from a diversified medical products firm into a focused, dual-platform medical technology company with strong global market positions.
Business Operations
The Cooper Companies conducts its operations through two reportable segments: CooperVision and CooperSurgical. CooperVision designs, manufactures, and markets a broad portfolio of soft contact lenses, including daily disposable, monthly, toric, and multifocal lenses, serving optometrists, ophthalmologists, and optical retailers. This segment represents the company’s largest revenue driver and benefits from recurring consumer demand and global distribution.
CooperSurgical operates across women’s health and fertility markets, offering products and services used in in vitro fertilization (IVF), contraception, obstetrics, and gynecology. The segment includes medical devices, surgical instruments, and fertility clinic services. Operations are supported by proprietary technologies, regulated manufacturing facilities, and a portfolio of specialized brands and subsidiaries, with revenue generated through both product sales and clinical service offerings.
Strategic Position & Investments
The Cooper Companies’ strategy emphasizes organic growth, targeted acquisitions, and expansion in specialized healthcare markets with durable demand drivers. The company has consistently invested in expanding its contact lens portfolio, particularly in silicone hydrogel and myopia management technologies, while also scaling its fertility and women’s health platforms through acquisitions.
Notable strategic investments include the expansion of CooperSurgical through acquisitions of fertility service providers and medical device companies, strengthening its presence across the IVF value chain. The company continues to invest in emerging reproductive health technologies, data-driven fertility solutions, and next-generation vision correction products, aligning its portfolio with long-term demographic and healthcare trends.
Geographic Footprint
The Cooper Companies is headquartered in the United States and operates on a global scale, with significant market presence across North America, Europe, and Asia-Pacific. Manufacturing, research, and distribution facilities are located in multiple countries, supporting regional customization and regulatory compliance.
International markets represent a substantial portion of revenue, particularly for CooperVision, which has strong positions in Europe and Asia. Through subsidiaries and operating entities worldwide, the company maintains a diversified geographic footprint that reduces reliance on any single market and supports long-term international growth.
Leadership & Governance
The Cooper Companies is led by an experienced executive team with deep expertise in medical devices, healthcare services, and global operations. The leadership emphasizes disciplined capital allocation, innovation-driven growth, and long-term value creation within regulated healthcare markets.
Key executives include:
- Albert G. White III – President and Chief Executive Officer
- Kyle L. Pendrey – Chief Financial Officer and Treasurer
- Daniel E. McBride – Chief Operating Officer
- Paul L. Kaufman – Senior Vice President and Chief Medical Officer
- Thomas J. Mahoney – Senior Vice President, General Counsel, and Corporate Secretary
The company’s governance framework aligns executive incentives with performance, regulatory compliance, and shareholder interests, supporting its strategic focus on sustainable growth and operational excellence.